Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • AltheRx, Velicept deal

    AltheRx Pharmaceuticals, Exton, Pa. Velicept Therapeutics Inc., Malvern, Pa. Business: Autoimmune, Genitourinary Velicept will merge with AltheRx, and the surviving company will retain Velicepts name and focus on the …

    Published on 7/27/2015
  • ArmaGen, Shire deal

    ArmaGen Technologies Inc., Calabasas, Calif. Shire plc (LSE:SHP;NASDAQ:SHPG), Dublin, Ireland Business: Endocrine/Metabolic ArmaGen Inc. (formerly ArmaGen Technologies Inc.) received an undisclosed milestone payment …

    Published on 7/27/2015
  • Bio-Reference Laboratories, Opko deal

    Bio-Reference Laboratories Inc. (NASDAQ:BRLI), Elmwood Park, N.J. Opko Health Inc. (NYSE:OPK;Tel Aviv:OPK), Miami, Fla. Business: Supply/Service Opko will acquire clinical service laboratory Bio-Reference for $1.5 …

    Published on 7/27/2015
  • Bristol-Myers, Genmab deal

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Genmab A/S (CSE:GEN;OTCBB:GMXAY), Copenhagen, Denmark Business: Cancer Bristol-Myers granted Genmab an exclusive license to a panel of human antibodies targeting CD19 …

    Published on 7/27/2015
  • CleveXel Pharma, PEP-Therapy deal

    CleveXel Pharma S.A.S., Maisons-Alfort, France PEP-Therapy S.A.S., Evry, France Business: Cancer The companies partnered to co-develop a peptide from PEP-Therapy to treat cancer through clinical proof of concept. The …

    Published on 7/27/2015
  • Dara BioSciences, Midatech Pharma deal

    Dara BioSciences Inc. (NASDAQ:DARA), Raleigh, N.C. Midatech Pharma plc (LSE:MTPH), Abingdon, U.K. Business: Neurology, Infectious Midatech will acquire Dara BioSciences for 5.4 million Midatech shares valued at L15.7 …

    Published on 7/27/2015
  • Fate Therapeutics, Boston Childrens Hospital deal

    Fate Therapeutics Inc. (NASDAQ:FATE), San Diego, Calif. Boston Childrens Hospital, Boston, Mass. Business: Autoimmune, Endocrine/Metabolic, Inflammation Under a two-year deal, the hospital will assess Fates PD-L1 …

    Published on 7/27/2015
  • Humabs BioMed, Novartis deal

    Humabs BioMed S.A., Bellinzona, Switzerland Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Infectious, Antibodies Humabs received an undisclosed milestone payment from Novartis under a 2009 deal granting …

    Published on 7/27/2015
  • Iroko, Laboratorios Saval deal

    Iroko Pharmaceuticals LLC, Philadelphia, Pa. Laboratorios Saval S.A., Santiago, Chile Business: Neurology Iroko granted Laboratorios Saval exclusive rights to develop and commercialize Zorvolex submicron diclofenac in …

    Published on 7/27/2015
  • Jazz Pharmaceuticals, Aytu deal

    Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland Aytu BioScience Inc. (OTCQB:AYTU), Englewood, Colo. Business: Diagnostic Aytu purchased ProstaScint from Jazz for $1.7 million up front. Aytu will pay Jazz 8% of …

    Published on 7/27/2015
  • Memcine, Spotlight Innovation deal

    Memcine Pharmaceuticals Inc., Coralville, Iowa Spotlight Innovation Inc. (OTCQB:STLT), West Des Moines, Iowa Business: Infectious Spotlight acquired an 82% stake in Memcine, which is developing its Immunoplex vaccine …

    Published on 7/27/2015
  • Omeros, Fagron deal

    Omeros Corp. (NASDAQ:OMER), Seattle, Wash. Fagron N.V. (Euronext:FAGR), Waregem, Belgium Business: Neurology Omeros granted Fagron exclusive rights to commercialize OMS103 in the U.S. Fagron will pay Omeros a majority …

    Published on 7/27/2015
  • Peptinnovate, MRC deal

    Peptinnovate Ltd., London, U.K. MRC Technology, London, U.K. Business: Musculoskeletal Peptinnovate and MRC partnered to evaluate the therapeutic potential of Pepinnovates peptides, which are derived from Mycobacterium …

    Published on 7/27/2015
  • ProSolus, Mission Pharmacal deal

    ProSolus Pharmaceuticals L.P., Miami, Fla. Mission Pharmacal Co., San Antonio, Texas Business: Drug delivery Mission Pharmacal acquired ProSolus for an undisclosed sum. ProSolus develops and manufactures transdermal …

    Published on 7/27/2015
  • Rexahn, National Cancer Institute deal

    Rexahn Pharmaceuticals Inc. (NYSE-M:RNN), Rockville, Md. National Cancer Institute, Bethesda, Md. Business: Cancer Rexahn said the NCIs Nanotechnology Characterization Laboratory (NCL) accepted RX-21101 for a …

    Published on 7/27/2015
  • Roche, DalCor deal

    Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland DalCor Pharmaceuticals Canada Inc., Montreal, Quebec Business: Cardiovascular Roche granted DalCor exclusive, worldwide rights to develop and commercialize dalcetrapib. …

    Published on 7/27/2015
  • Roche, DalCor deal

    Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland DalCor Pharmaceuticals Canada Inc., Montreal, Quebec Business: Pharmacogenetics Roche will develop a companion diagnostic for DalCors dalcetrapib. The test will be used in…

    Published on 7/27/2015
  • Sun Pharma, Sun Pharmaceutical deal

    Sun Pharma Advanced Research Company Ltd. (BSE:524715;NSE:SPARC), Mumbai, India Sun Pharmaceutical Industries Ltd. (BSE:524715;NSE:SUNPHARMA), Mumbai, India Business: Ophthalmic SPARC granted Sun U.S. rights to Xelpros …

    Published on 7/27/2015
  • Swedish Orphan Biovitrum deal

    Swedish Orphan Biovitrum AB (SSE:SOBI), Stockholm, Sweden Business: Hematology The board of Swedish Orphan terminated discussions regarding an unsolicited, non-binding bid to acquire the company. The company said it …

    Published on 7/27/2015
  • University of Pennsylvania, WuXi PharmaTech deal

    University of Pennsylvania, Philadelphia, Pa. WuXi PharmaTech Inc. (NYSE:WX), Shanghai, China Business: Supply/Service WuXi and the university partnered to establish scalable manufacturing processes to produce cGMP …

    Published on 7/27/2015
  • University of Pittsburgh, Asana Medical deal

    University of Pittsburgh, Pittsburgh, Pa. Asana Medical Inc., Miami Lakes, Fla. Business: Autoimmune The university granted Asana exclusive, worldwide rights to multiple patents and patent applications covering methods …

    Published on 7/27/2015
  • Vect-Horus, Servier deal

    Vect-Horus, Marseille, France Servier, Neuilly-sur-Seine, France Business: Neurology The companies partnered to generate new chemical entities by applying Vect-Horus vector technology to CNS drug candidates from Servier…

    Published on 7/27/2015
  • Weill Cornell Medical College, Cellectis deal

    Weill Cornell Medical College, New York, N.Y. Cellectis S.A. (Euronext:ALCLS;NASDAQ:CLLS), Paris, France Business: Cancer Weill Cornell and Cellectis partnered to develop Cellectis UCART123 -- chimeric antigen receptor…

    Published on 7/27/2015
  • Abeona Therapeutics, University of Nebraska deal

    Abeona Therapeutics Inc. (NASDAQ:ABEO), Dallas, Texas University of Nebraska, Lincoln, Neb. Business: Neurology The UNeMed Corp. tech transfer arm of the universitys medical center granted Abeona exclusive, worldwide …

    Published on 7/20/2015
  • AC Immune, Roche, Genentech deal

    AC Immune S.A., Lausanne, Switzerland Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Genentech Inc., South San Francisco, Calif. Business: Neurology AC Immune received an undisclosed milestone payment from Roches …

    Published on 7/20/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993